Theravance shows genuine fundamental quality — a wide moat and strong cash returns — but the market has already priced in most of the near-term upside, and recent earnings misses plus a negative risk/reward setup argue for caution rather than adding to the position.
Thesis pillars
- Wide Moat Quality Compounding→Stable
- Consecutive Earnings Miss Streak→Stable
- Analyst Target Already Reached→Stable
- +1 more pillar — see the Why tab for full reasoning
Theravance Biopharma, Inc. (TBPH) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. At $17.00, A.R:R is negative (-3.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUPELRI; Concentration risk — Supplier: YUPELRI API and drug product suppliers.
Theravance Biopharma is a biopharmaceutical company whose sole commercial product is YUPELRI (revefenacin), an FDA-approved inhaled treatment for chronic obstructive pulmonary disease co-developed and commercialized with partner Viatris, which generated $266.6 million in net... Read more
Sell if holding. At $17.00, A.R:R is negative (-3.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUPELRI; Concentration risk — Supplier: YUPELRI API and drug product suppliers. Chart setup: RSI 58 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 36d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
About Theravance Biopharma, Inc.
About Theravance Biopharma, Inc.
YUPELRI, Theravance Biopharma's only commercial product, generated $266.6 million in net sales in 2025 through partner Viatris, up 12% year over year, with Theravance recording a 35% share of net profit in the US and tiered royalties outside the US. The company also retains rights to up to $150 million in additional TRELEGY milestone payments from Royalty Pharma after selling its remaining TRELEGY royalty interest to GSK for $225 million in 2025. Following the March 2026 failure of ampreloxetine's Phase 3 CYPRESS study, Theravance is winding down its R&D function and cutting operating expenses by approximately 60% relative to 2025's $111.1 million.
Theravance earns revenue through a 65/35 profit-split with Viatris on US YUPELRI sales, tiered royalties ranging from low double-digits to mid-teens on ex-US sales (excluding China), and tiered royalties of 14% to 20% on China-region sales once Viatris, which holds exclusive China rights, reaches certain net-sales thresholds. Manufacturing is fully outsourced: a single supplier produces YUPELRI's active pharmaceutical ingredient, a single supplier makes the finished drug product, and the product is warehoused at a single facility, with no long-term supply agreements guaranteeing continuity. Multiple patents covering YUPELRI run through 2039, though the company has already settled Paragraph IV patent challenges with several generic applicants by granting them royalty-free licenses to launch on or after April 23, 2039.
Show full overview
Theravance's near-term story is no longer about pipeline binary risk but about what happens after one materialized: the March 2026 failure of the CYPRESS trial ended the company's only wholly-owned clinical program, and the Board's Strategic Review Committee, working with financial advisor Lazard since 2024, is now acting with urgency to evaluate alternatives including an outright sale of the company. That same single-source supply chain that underpins YUPELRI's commercial success is also a structural vulnerability: with one API supplier, one drug-product manufacturer, and one warehouse location, any regulatory or operational disruption at any of those three sites could interrupt the revenue stream the Strategic Review Committee is trying to monetize.
See also: Healthcare · Biotechnology
From Theravance Biopharma, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Theravance Biopharma, Inc.
Material events (past 30 days)
- 8K Jun 23, 2026 MEDIUM Item 5.02: Áine Miller, SVP Development and Head of Ireland Office, will terminate employment effective November 15, 2026 under a compromise agreement tied to the March 2026 restructuring. Company will make a $250,000 pension contribution; she also received a grant of 18,750 restricted share units for continue
Latest news
- NEWS HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17 — benzinga Jul 7, 2026 negative
- NEWS Jones Trading Downgrades Theravance Biopharma to Hold — benzinga Jun 29, 2026 negative
- NEWS BTIG Downgrades Theravance Biopharma to Neutral — benzinga Jun 29, 2026 negative
- NEWS Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition — benzinga Jun 29, 2026 positive
- NEWS Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks — benzinga Jun 29, 2026 negative
Generated 2026-07-08T23:03:59Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductYUPELRI10-K Item 1A: 'The commercial success of YUPELRI depends upon its acceptance by physicians, patients, third-party payors and the medical community in general.'
- HIGHSupplierYUPELRI API and drug product suppliers10-K Item 1A: 'There is a single supplier of YUPELRI API, a single supplier of YUPELRI drug product and YUPELRI is warehoused in a single facility.'
- HIGHcounterpartyViatris10-K Item 1A: 'In collaboration with Viatris, we are responsible for marketing and sales of YUPELRI in the US, which subjects us to certain risks.'
Material Events(8-K, last 90d)
- 2026-06-23Item 5.02MEDIUMÁine Miller, SVP Development and Head of Ireland Office, will terminate employment effective November 15, 2026 under a compromise agreement tied to the March 2026 restructuring. Company will make a $250,000 pension contribution; she also received a grant of 18,750 restricted share units for continued service through the termination date.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $17.00, A.R:R is negative (-3.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUPELRI; Concentration risk — Supplier: YUPELRI API and drug product suppliers. Chart setup: RSI 58 mid-range, Bollinger mid-band. Prior stop was $16.30. Score 5.4/10, moderate confidence.
Take-profit target: $17.39 (+2.3% upside). Prior stop was $16.30. Stop-loss: $16.30.
Concentration risk — Product: YUPELRI; Concentration risk — Supplier: YUPELRI API and drug product suppliers; Analyst target reached - limited upside remaining.
Theravance Biopharma, Inc. trades at a P/E of 7.6 (forward 13.5). TrendMatrix value score: 6.3/10. Verdict: Sell.
11 analysts cover TBPH with a consensus score of 3.8/5. Average price target: $17.
What does Theravance Biopharma, Inc. do?Theravance Biopharma is a biopharmaceutical company whose sole commercial product is YUPELRI (revefenacin), an...
Theravance Biopharma is a biopharmaceutical company whose sole commercial product is YUPELRI (revefenacin), an FDA-approved inhaled treatment for chronic obstructive pulmonary disease co-developed and commercialized with partner Viatris, which generated $266.6 million in net sales in 2025 (a 35% profit share to Theravance in the US). After its ampreloxetine Phase 3 program (CYPRESS) failed its primary endpoint in March 2026, the company is winding down R&D and cutting G&A by about 60%, while a Strategic Review Committee formed in 2024 evaluates alternatives including a possible sale; Theravanc